Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment

Leukemia. 2024 Feb;38(2):398-402. doi: 10.1038/s41375-023-02127-0. Epub 2024 Jan 11.

Gerulf Hänel^{1

2}, Anne Schönle³, Anne-Sophie Neumann^{1

2}, Daniel Nixdorf^{1

2}, Nora Philipp^{1

2}, Monika Sponheimer^{1

2}, Alexandra Leutbecher^{1

2}, Alica-Joana Emhardt¹, Giulia Magno¹, Veit Bücklein^{1

2}, Jan Eckmann⁴, Diana Dunshee⁵, Vesna Kramar³, Koorosh Korfi³, Sara Colombetti³, Pablo Umaña³, Christian Klein⁶, Marion Subklewe^{7

8

9}

¹ Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
² Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.
³ Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
⁴ Roche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany.
⁵ Genentech Inc., South San Francisco, CA, USA.
⁶ Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland. christian.klein.ck1@roche.com.
⁷ Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. marion.subklewe@med.uni-muenchen.de.
⁸ Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany. marion.subklewe@med.uni-muenchen.de.
⁹ German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. marion.subklewe@med.uni-muenchen.de.

No abstract available

Publication types